MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-25-2026
Atossa Therapeutics ROA Ratio 2011-2026 | ATOS
Annual ROA Ratio Atossa Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -73.03 | -33.36 | -31.27 | -21.82 | -14.59 | -41.62 | -118.98 | -97.31 | -99.49 | -153.68 | -252.43 | -124.6 | -89.8 | -74.42 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -14.59 | -252.43 | -87.6 |
Quarterly ROA Ratio Atossa Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -46.63 | -40.75 | -34.74 | -22.6 | -28.72 | -25.75 | -27.78 | -20.6 | -26.92 | -27.12 | -23.03 | -14.78 | -18.41 | -15.73 | -15.57 | -10.97 | -19.12 | -23.63 | -27.92 | -24.15 | -46.82 | -61.35 | -102.36 | -100.91 | -129.15 | -134.71 | -119.94 | -79.58 | -106.33 | -104.85 | -96.96 | -153.43 | -148.49 | -116.79 | -130.9 | -92.78 | -161.95 | -236.05 | -244.87 | -172.96 | -200.55 | -158.98 | -135.7 | -75.19 | -104.35 | -105.92 | -100.33 | -66.84 | -83.59 | -71.18 | -66.78 | -49.43 | -90.86 | -115.54 | -98.43 | - | -41.43 | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -10.97 | -244.87 | -82.16 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M |  USA |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Nanobiotix S.A.
NBTX
|
-46.19 | $ 30.34 | -0.82 % | $ 286 B |  France |
 |
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Akebia Therapeutics
AKBA
|
-1.42 | $ 1.4 | -0.71 % | $ 360 M | USA |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B | France |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
-218.41 | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 95.5 | 3.83 % | $ 27.2 B | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 2.92 | -0.34 % | $ 6.35 B |  Israel |
 |
Aytu BioScience
AYTU
|
-10.92 | $ 2.55 | -0.78 % | $ 16 M | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
AstraZeneca PLC
AZN
|
0.11 | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
6.02 | $ 20.37 | -2.4 % | $ 952 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1008.51 | - | -2.5 % | $ 5.88 M | USA |
 |
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.08 | -2.16 % | $ 436 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 24.21 | -1.47 % | $ 3.08 B | USA |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
Celldex Therapeutics
CLDX
|
-44.38 | $ 32.24 | -4.1 % | $ 2.14 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-24.24 | - | - | $ 3.45 B | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Cabaletta Bio
CABA
|
-101.68 | $ 3.13 | -1.26 % | $ 315 M | USA |
 |
Codiak BioSciences
CDAK
|
-21.64 | - | -55.98 % | $ 2.15 M | USA |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
Avid Bioservices
CDMO
|
-41.82 | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
-79.06 | - | - | $ 1.41 B | USA |
 |
InflaRx N.V.
IFRX
|
-36.46 | $ 1.0 | -2.91 % | $ 152 M | Germany |
 |
Immutep Limited
IMMP
|
-36.45 | $ 0.31 | -2.52 % | $ 1.08 B |  Australia |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
-752.78 | - | - | $ 169 M | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Concert Pharmaceuticals
CNCE
|
-48.42 | - | - | $ 401 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-36.12 | $ 3.83 | -2.3 % | $ 258 B | Britain |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Celsion Corporation
CLSN
|
-117.96 | - | -6.63 % | $ 13.9 M | USA |